Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. [electronic resource]
Producer: 20040105Description: 730-7 p. digitalISSN:- 0007-1048
- Acid Phosphatase -- blood
- Adult
- Alkaline Phosphatase -- blood
- Anti-Inflammatory Agents -- administration & dosage
- Biomarkers -- blood
- Blood Transfusion
- Bone Density -- drug effects
- Carrier Proteins -- blood
- Case-Control Studies
- Collagen -- urine
- Collagen Type I
- Diphosphonates -- administration & dosage
- Drug Administration Schedule
- Female
- Glycoproteins -- blood
- Humans
- Isoenzymes -- blood
- Lumbar Vertebrae
- Male
- Membrane Glycoproteins -- blood
- Middle Aged
- Osteocalcin -- blood
- Osteoporosis -- drug therapy
- Osteoprotegerin
- Pamidronate
- Peptides -- urine
- RANK Ligand
- Receptor Activator of Nuclear Factor-kappa B
- Receptors, Cytoplasmic and Nuclear -- blood
- Receptors, Tumor Necrosis Factor
- Statistics, Nonparametric
- Tartrate-Resistant Acid Phosphatase
- beta-Thalassemia -- complications
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.